地奥司明联合α-受体阻滞剂治疗ⅢB型前列腺炎的疗效观察

王家菁; 杨盛; 陈永华; 张军; 刘佳; 赵纪宇; 肖飞; 谷现恩

doi:10.13898/j.cnki.issn.1000-2200.2018.09.017

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

地奥司明联合α-受体阻滞剂治疗ⅢB型前列腺炎的疗效观察

王家菁 , 杨盛 , 陈永华 , 张军 , 刘佳 , 赵纪宇 , 肖飞 , 谷现恩

文章导航 > 蚌埠医学院学报 > 2018, 43 > 9: (1176-1178)

引用本文:

Citation:

地奥司明联合α-受体阻滞剂治疗ⅢB型前列腺炎的疗效观察

清华大学附属垂杨柳医院泌尿中心, 100022

作者简介: 王家菁(1968-),男,博士,副主任医师.

中图分类号: R697.33

The curative effect observation of diosmin combined with α-blockers in the treatment of typeⅢ B prostatitis

Urology Center, Chuiyangliu Hospital Affiliated to Tsinghua University, Beijing 100022, China
CLC number: R697.33

摘要: 目的：探讨地奥司明联合α-受体阻滞剂治疗ⅢB型前列腺炎的治疗效果。方法：选择200例ⅢB型前列腺炎病人，随机均分为2组，对照组仅用坦索罗辛治疗，观察组采用地奥司明联合α-受体阻滞剂坦索罗辛进行治疗，比较2组病人治疗前后慢性前列腺炎症状指数评分（NIH-CPSI）、国际勃起功能指数评分（ⅡEF-5）、生活质量评分（QOL）情况，对2组病人进行疗效评价并观察不良反应的发生情况。结果：治疗前，2组病人各项临床症状评分差异无统计学意义（P>0.05）。2组病人治疗后NIH-CPSI、QOL均较治疗前降低，ⅡEF-5评分较治疗前升高，且观察组病人治疗后的NIH-CPSI评分、QOL评分均低于对照组，ⅡEF-5评分高于对照组（P<0.05~P<0.01）。观察组总有效率达90%，高于对照组的70%（P<0.05）。2组不良反应发生率差异无统计学意义（P>0.05）。结论：采用地奥司明联合坦索罗辛治疗ⅢB型前列腺炎能够显著改善病人的性功能，提高生活质量，治疗效果好，不良反应轻微。
- 前列腺炎 /
- 地奥司明 /
- α-受体阻滞剂
Abstract: Objective:To investigate the clinical effects of diosmin combined with α-blockers in the treatment of type Ⅲ B prostatitis.Methods:Two hundred patients with type Ⅲ B prostatitis were randomly divided into the control group and observation group(100 cases each group).The control group and observation group were treated with tamsulosin and diosmin combined with α-blockers,respectively.The chronic prostatitis index score(NIH-CPSI),international index of erectile function score(ⅡEF-5) and quality of life score(QOL) between two groups before and after treatment were compared.The curative effects in two groups were evaluated,and the occurrence of adverse reactions in two groups were observed.Results:Before treatment,the differences of all item scores between two groups were not statistically significant(P>0.05).Compared with before treatment,the NIH-CPSI score and QOL score in two groups decreased,and the ⅡEF-5 score increased after treatment.After treatment,the NIH-CPSI score and QOL score in observation group were lower than those in control group,and the ⅡEF-5 score in observation group was higher than that in control group(P<0.05 to P<0.01).The total effective rate in observation group(90%) was significantly higher than that in control group(70%)(P<0.05),and the difference of the incidence rate of adverse reactions between two groups was not statistically significant(P>0.05).Conclusions:Diosmin combined with tamsulosin in treating type Ⅲ B prostatitis can significantly improve the patient's sexual function and quality of life,which has good effect and mild adverse reactions.
- prostatitis /
- diosmin /
- α-blocker

[1]	米华,陈凯,莫曾南.中国慢性前列腺炎的流行病学特征[J].中华男科学,2012,18(7):579.
[2]	梁朝朝.慢性前列腺炎诊断标准的再认识[J].现代泌尿外科杂志,2013,17(6):537.
[3]	黎凤明,田晓东,胡国文,等.地奥司明的临床应用进展[J].现代中西医结合杂志,2012,21(6):680.
[4]	何东林,林川,谢辉.慢性前列腺炎患者生活质量调查及其影响因素分析[J].中国男科学杂志,2012,26(1):32.
[5]	白剑,刘继红.药物治疗慢性前列腺炎进展[J].医药导报,2011,30(10):1319.
[6]	MAGRI V,MARRAS E,RESTELLI A,et al.Multimodal therapy for category Ⅲ chronic prostatitis/chronic pelvic pain syndrome in UPOINTS phenotyped patients[J].Exp Ther Med,2015,9(3):658.
[7]	李文哲,巩龙,王霖,等.地奥司明的药理活性研究进展[J].中国疗养医学,2012,21(10):887.
[8]	张小马,方军,龚强,等.纳米银水凝胶联合α-受体阻滞剂治疗Ⅲ型前列腺炎的对照研究[J].重庆医学,2010,39(22):3065.
[9]	崔功廷,袁铭.地奥司明对盆腔淤血所致大鼠慢性非细菌性前列腺炎的影响[J].解放军医学杂志,2014,39(6):444.
[10]	黄智超,赵晓昆,王荫槐.地奥司明片联合盐酸坦索罗辛缓释胶囊治疗ⅢB型前列腺炎的临床研究[J].临床泌尿外科杂志,2016,31(2):111.
[11]	PONTARI M,GIUSTO L.New developments in the diagnosis and treatment of chronic prostatitis/chronic pelvic pain syndrome[J].Curr Opin Urol,2013,23(6):565.
[12]	PONTARI MA.Etiology of chronic prostatitis/chronic pelvic pain syndrome:psychoimmunoneurendocrine dysfunction (PINE syndrome) or just a really bad infection[J].World J Urol,2013,31(4):725.

[1]	张红双 , 李杨亮 , 陆佳 . 急性前列腺炎患者血清前列腺特异性抗原的变化及其意义. 蚌埠医学院学报, 2014, 38(5): 627-629.
[2]	杨青松 , 胡月鹏 , 陶春杰 , 郭美荣 , 李辰 , 杜靖 . 经直肠超声导入前列腺治疗仪联合左氧氟沙星治疗前列腺炎的临床研究. 蚌埠医学院学报, 2019, 44(8): 1030-1034. doi: 10.13898/j.cnki.issn.1000-2200.2019.08.014
[3]	钱余 , 夏仁惠 , 周伟邦 , 刘剑新 , 田长海 , 韩孝洲 , 张勇 . 宁泌泰-特拉唑嗪与普适泰治疗慢性非细菌性前列腺炎. 蚌埠医学院学报, 2005, 30(3): 257-259.
[4]	王强荣 , 陈进 , 周鸣 , 陈丽红 , 袁小卫 . 联合应用MRI多种功能成像诊断前列腺癌的研究. 蚌埠医学院学报, 2013, 37(1): 93-96.
[5]	朱彩云 , 冯春颜 , 谭辉赟 , 邱群芳 . 深圳地区男性前列腺液白细胞计数检测分析. 蚌埠医学院学报, 2013, 37(9): 1184-1185.
[6]	王忠 , 戴红波 , 陈红 . β受体阻滞剂的围手术期应用. 蚌埠医学院学报, 2004, 29(4): 376-377.
[7]	杨小淮 , 李庆文 , 刘贝贝 , 薛胜 , 李建 . 经尿道前列腺电切术治疗良性前列腺增生134例. 蚌埠医学院学报, 2014, 38(5): 599-601.
[8]	何启胜 . 依帕司他联合前列地尔治疗糖尿病周围神经病变的临床观察. 蚌埠医学院学报, 2014, 38(3): 318-319,323.
[9]	许向辉 , 顾科 . 经尿道前列腺电切术麻醉处理. 蚌埠医学院学报, 2006, 31(5): 555-556.
[10]	刘峰 , 刘辉 , 郝继东 , 王伟峰 , 万建省 . 奥曲肽对人前列腺癌细胞生长周期的作用. 蚌埠医学院学报, 2013, 37(7): 792-794.
[11]	张黎明 , 齐秋江 . 经尿道前列腺电切术治疗小体积前列腺增生17例. 蚌埠医学院学报, 2009, 34(9): 783-785.
[12]	顾恒 , 王昌兵 , 李博 , 余同辉 , 叶大文 . 经尿道等离子前列腺切除术治疗良性前列腺增生120例. 蚌埠医学院学报, 2011, 36(7): 728-730.
[13]	姚少利 . 前列腺特异性抗原在前列腺癌中的诊断价值. 蚌埠医学院学报, 2013, 37(11): 1477-1479.
[14]	燕小朋 , 张学珍 , 梁姗 . 经直肠超声引导下前列腺穿刺活检结合血清PSA早期诊断前列腺癌价值. 蚌埠医学院学报, 2018, 43(5): 637-638. doi: 10.13898/j.cnki.issn.1000-2200.2018.05.022
[15]	钱永 , 杜永强 , 刘彬 , 单卫民 , 刘雷 . 经尿道双极等离子前列腺剜除术治疗良性前列腺增生40例临床分析. 蚌埠医学院学报, 2009, 34(8): 684-685.
[16]	唐飞 , 陈立军 , 李建涛 , 李学超 , 刘杰 , 曲楠 , 赵立 , 王亚林 , 黄晨 . 术前急性尿潴留留置导尿管对绿激光前列腺汽化术治疗前列腺增生症的影响. 蚌埠医学院学报, 2013, 37(2): 156-159;155.
[17]	张阳光 . 经尿道前列腺电切治疗老年良性前列腺增生的围手术期处理. 蚌埠医学院学报, 2015, 40(11): 1503-1505. doi: 10.13898/j.cnki.issn.1000-2200.2015.11.013
[18]	王二朋 , 戴廷山 , 范振永 , 詹扬 , 王海江 , 刘伟 , 曾建华 . 经尿道前列腺电切术联合气压弹道超声碎石清石术治疗前列腺增生合并膀胱结石效果观察. 蚌埠医学院学报, 2016, 41(3): 348-350. doi: 10.13898/j.cnki.issn.1000-2200.2016.03.022
[19]	朱克东 . 前列地尔、氟尿嘧啶治疗重症胰腺炎38例. 蚌埠医学院学报, 2005, 30(5): 450-451.
[20]	凌兴邦 . 前列腺增生经尿道电汽化术后药物镇痛效果比较. 蚌埠医学院学报, 2005, 30(5): 425-426.

点击查看大图

计量

文章访问数: 4245
HTML全文浏览量: 892
PDF下载量: 11
被引次数: 0

地奥司明联合α-受体阻滞剂治疗ⅢB型前列腺炎的疗效观察

作者简介: 王家菁(1968-),男,博士,副主任医师.

清华大学附属垂杨柳医院泌尿中心, 100022

收稿日期: 2016-12-16
录用日期: 2018-07-18

关键词:

摘要: 目的：探讨地奥司明联合α-受体阻滞剂治疗ⅢB型前列腺炎的治疗效果。方法：选择200例ⅢB型前列腺炎病人，随机均分为2组，对照组仅用坦索罗辛治疗，观察组采用地奥司明联合α-受体阻滞剂坦索罗辛进行治疗，比较2组病人治疗前后慢性前列腺炎症状指数评分（NIH-CPSI）、国际勃起功能指数评分（ⅡEF-5）、生活质量评分（QOL）情况，对2组病人进行疗效评价并观察不良反应的发生情况。结果：治疗前，2组病人各项临床症状评分差异无统计学意义（P>0.05）。2组病人治疗后NIH-CPSI、QOL均较治疗前降低，ⅡEF-5评分较治疗前升高，且观察组病人治疗后的NIH-CPSI评分、QOL评分均低于对照组，ⅡEF-5评分高于对照组（P<0.05~P<0.01）。观察组总有效率达90%，高于对照组的70%（P<0.05）。2组不良反应发生率差异无统计学意义（P>0.05）。结论：采用地奥司明联合坦索罗辛治疗ⅢB型前列腺炎能够显著改善病人的性功能，提高生活质量，治疗效果好，不良反应轻微。

English Abstract

The curative effect observation of diosmin combined with α-blockers in the treatment of typeⅢ B prostatitis

Urology Center, Chuiyangliu Hospital Affiliated to Tsinghua University, Beijing 100022, China

Received Date: 2016-12-16
Accepted Date: 2018-07-18

Abstract: Objective:To investigate the clinical effects of diosmin combined with α-blockers in the treatment of type Ⅲ B prostatitis.Methods:Two hundred patients with type Ⅲ B prostatitis were randomly divided into the control group and observation group(100 cases each group).The control group and observation group were treated with tamsulosin and diosmin combined with α-blockers,respectively.The chronic prostatitis index score(NIH-CPSI),international index of erectile function score(ⅡEF-5) and quality of life score(QOL) between two groups before and after treatment were compared.The curative effects in two groups were evaluated,and the occurrence of adverse reactions in two groups were observed.Results:Before treatment,the differences of all item scores between two groups were not statistically significant(P>0.05).Compared with before treatment,the NIH-CPSI score and QOL score in two groups decreased,and the ⅡEF-5 score increased after treatment.After treatment,the NIH-CPSI score and QOL score in observation group were lower than those in control group,and the ⅡEF-5 score in observation group was higher than that in control group(P<0.05 to P<0.01).The total effective rate in observation group(90%) was significantly higher than that in control group(70%)(P<0.05),and the difference of the incidence rate of adverse reactions between two groups was not statistically significant(P>0.05).Conclusions:Diosmin combined with tamsulosin in treating type Ⅲ B prostatitis can significantly improve the patient's sexual function and quality of life,which has good effect and mild adverse reactions.